+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels



Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels



Fertility and Sterility 71(2): 261-267



Objective: To determine the effects of menopause and three different formulations of E2 plus medroxyprogesterone acetate on serum concentrations of basal and growth hormone-releasing hormone (GHRH)-stimulated growth hormone (GH), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein (IGFBP)-1, IGFBP-3, insulin, and C peptide. Design: Prospective, controlled trial. Setting: Menopausal outpatient clinic at an academic tertiary care hospital. Patient(s): Nineteen postmenopausal women with different menopausal ages. Seventeen premenopausal women were included as controls. Intervention(s): Oral estrogen (E2 valerate, 2 mg/d) or transdermal estrogen (50-mug or 100-mug E2 patch) was administered for 8 weeks. Medroxyprogesterone acetate (5 mg/d) was administered during weeks 3, 4, 7, and 8 of each protocol. Blood samples were collected before treatment and after the completion of each protocol from postmenopausal women, and on cycle days 6-8 from premenopausal women. Main Outcome Measure(s): Levels of GH, IGF-1, IGFBP-1, IGFBP-3, insulin, and C peptide. Result(s): Basal GH levels were negatively correlated with age in premenopausal women but not in postmenopausal women. The area under the GHRH-induced GH curve decreased in older postmenopausal women after the oral estrogen protocol. Levels of IGF-1 diminished after the oral E2 protocol in postmenopausal women. Conclusion(s): The administration of oral, but not transdermal, E2 plus medroxyprogesterone acetate at the usual clinical doses used in postmenopausal women decreased IGF-1 levels and the response of GH to GHRH in older women. No substantial changes were detected in IGFBP-1, IGFBP-3, insulin, or C peptide levels.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010528910

Download citation: RISBibTeXText

PMID: 9988395

DOI: 10.1016/s0015-0282(98)00432-4


Related references

The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 94(2): 588-595, 2009

Western ligand blot assay for human growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3): the serum levels in patients with classical growth hormone deficiency. Endocrinologia Japonica 39(1): 121-127, 1992

Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. Journal of Endocrinology 154(2): 319-328, 1997

Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clinical Endocrinology 53(3): 329-336, 2000

Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. Journal of Endocrinology 136(1): 91-104, 1993

Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the Southwest Pediatric Nephrology Study Group. Journal of Clinical Endocrinology and Metabolism 84(2): 596-601, 1999

17beta-estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypoestrogenic, hypergonadotropic women. Endokrynologia Polska 56(6): 876-882, 2006

Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. International Journal of Obesity and Related Metabolic Disorders 21(5): 355-359, 1997

Effect of obesity on total and free insulin-like growth factor -1, and their relationship to IGF-binding protein -1, IGFBP-2, IGFBP-3, insulin, and growth hormone. International Journal of Obesity 21(5): 355-359, 1997

Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. Journal of Clinical Endocrinology and Metabolism 89(5): 2290-2300, 2004

Effect of active immunization against growth hormone releasing factor grfi on follicular growth serum and follicular insulin like growth factor i igf i and igf binding proteins igfbp and onset on puberty in heifers. Journal of Animal Science 70(Suppl. 1): 275, 1992

Use of insulin-like growth factor-binding protein-2 (Igfbp-2), Igfbp-3, and Igf-I for assessing growth hormone status in short children. Journal of Clinical Endocrinology & Metabolism 77(5): 1294-1299, 1993

Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. Journal of Clinical Endocrinology and Metabolism 77(5): 1294-1299, 1993

Transforming growth factor-alpha stimulates insulin-like growth factor binding protein-4 (IGFBP-4) expression and blocks follicle-stimulating hormone regulation of IGFBP-4 production in rat granulosa cells. Molecular and Cellular Endocrinology 133(1): 9-17, 1997

Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. Journal of Medical Case Reports 4: 305, 2010